XYLOCOR THERAPEUTICS
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patients with refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.
XYLOCOR THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2013-01-01
Address:
Wayne, Pennsylvania, United States
Country:
United States
Website Url:
http://www.xylocor.com
Total Employee:
1+
Status:
Active
Contact:
888-290-0081
Email Addresses:
[email protected]
Total Funding:
39.6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Apache ReCAPTCHA JsDelivr AJAX Libraries API ReCAPTCHA V2 CPanel SSL
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Current Advisors List
Current Employees Featured
Founder
Investors List
Longwood Fund
Longwood Fund investment in Series A - XyloCor Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series A - XyloCor Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series A - XyloCor Therapeutics
Lumira Ventures
Lumira Ventures investment in Series A - XyloCor Therapeutics
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - XyloCor Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series A - XyloCor Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series A - XyloCor Therapeutics
Official Site Inspections
http://www.xylocor.com
- Host name: 69.174.115.195
- IP address: 69.174.115.195
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "XyloCor Therapeutics"
Company Overview - XyloCor
XyloCor founders Dr. Ronald Crystal and Dr. Todd Rosengart started their collaboration in the 1990s at Weill Cornell Medical College where they combined their expertise in gene therapy …See details»
XyloCor Therapeutics - Crunchbase Company Profile
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new …See details»
XyloCor Therapeutics, Inc. - LinkedIn
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.See details»
XyloCor Therapeutics Company Profile 2024: Valuation, Funding ...
EQT Life Sciences, Fountain Healthcare Partners, Longwood Fund, Lumira Ventures, and Sofinnova Investments have invested in XyloCor Therapeutics. Who are XyloCor …See details»
Xylocor Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Xylocor Therapeutics, Inc. of King OF Prussia, PA. Get the latest business insights from Dun & …See details»
XyloCor Therapeutics - Contacts, Employees, Board Members, …
Organization. XyloCor Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 9. Number of …See details»
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to ...
3 days ago KING OF PRUSSIA, Pa., January 07, 2025--XyloCor Therapeutics, Inc., ("XyloCor"), a clinical stage biopharmaceutical company developing novel gene therapies for …See details»
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to ...
XyloCor Therapeutics, Inc. is a private, clinical‑stage biopharmaceutical company developing potential best‑in‑class gene therapies to transform outcomes for patients with cardiovascular …See details»
XyloCor Raises $67.5M in Series B Financing
1 day ago NEW YORK – XyloCor Therapeutics on Tuesday said it has raised $67.5 million in Series B financing, which it will use to further develop a gene therapy for cardiovascular …See details»
XyloCor gets $67.5 million to test heart disease gene therapy
2 days ago XyloCor employs 10 people, and plans to add to staff this year, a spokesperson said. The company’s potential gene therapy product is based on technology licensed from Cornell …See details»
XyloCor Therapeutics, Inc. - Center For Technology Licensing
Mar 20, 2018 XyloCor Therapeutics, Inc. March 20, 2018 October 6th, 2022. Home » Startups » XyloCor Therapeutics, Inc. Tweet Share. XyloCor is a clinical-stage biotechnology company …See details»
XyloCor Therapeutics - Craft
XyloCor Therapeutic is a biopharmaceutical company which is engaged in developing of gene therapy for cardiovascular diseases. The Company develops products for patients with …See details»
XyloCor Therapeutics, Inc. Management Team | Org Chart
XyloCor Therapeutics, Inc. employs 19 employees. The XyloCor Therapeutics, Inc. management team includes Al Gianchetti (President and CEO), Alexander Gaidamaka (Chief Technology …See details»
XyloCor – Gene therapy for advanced coronary artery disease
XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy. Latest News. XyloCor …See details»
XyloCor Therapeutics | The Pharmaletter
2 days ago XyloCor Therapeutics A clinical stage biopharmaceutical company developing novel gene therapies for cardiovascular disease. The company's lead drug candidate is XC001 …See details»
XyloCor raises $67.5M Series B, updates pivotal gene therapy trial …
3 days ago XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says Phase 2 studies could report late 2026.See details»
News - XyloCor
XyloCor’s latest news. Wayne, PA, May 2, 2024 — XyloCor Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, …See details»
XyloCor bags $23M to expand heart disease gene therapy R&D
Mar 22, 2021 XyloCor raised $17 million late in 2018, putting it on a track that led to the initiation of a phase 1/2 trial in refractory angina last year. Now, XyloCor has raised a further $22.6 …See details»
Xylocor Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
XyloCor Therapeutics is a biopharmaceutical organization dedicated to creating gene therapy solutions for individuals with severe coronary artery disease. The primary objective of this …See details»
XyloCor - VentureRadar
" XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, …See details»